Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Maryland is becoming the home away from home for British drugmaker AstraZeneca. | Maryland is becoming the home away from ...

After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with ...

Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius ...